Literature DB >> 28523101

Design and Synthesis of Potent and Selective PIM Kinase Inhibitors by Targeting Unique Structure of ATP-Binding Pocket.

Hirofumi Nakano1, Tsukasa Hasegawa1, Hirotatsu Kojima1, Takayoshi Okabe1, Tetsuo Nagano1.   

Abstract

In the development of kinase inhibitors, one of the major concerns is selectivity. An effective strategy to achieve high selectivity is to utilize structural differences among kinases to inform inhibitor design. Here, we set out to improve the PIM (proviral integration site for Moloney murine leukemia virus) kinase-inhibitory selectivity of our previously reported 7-azaindole derivative 2, which has promising ADMET properties, by targeting a unique bulge in the ATP-binding pocket. 6-Substituted 7-azaindoles, especially the 6-chlorinated derivatives, proved to be potent and selective PIM kinase inhibitors and appear to be promising lead compounds for future drug discovery.

Entities:  

Keywords:  ADMET; PIM kinase; kinase inhibitor; kinase selectivity; structure−based drug design

Year:  2017        PMID: 28523101      PMCID: PMC5430388          DOI: 10.1021/acsmedchemlett.6b00518

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  28 in total

1.  Discovery of novel benzylidene-1,3-thiazolidine-2,4-diones as potent and selective inhibitors of the PIM-1, PIM-2, and PIM-3 protein kinases.

Authors:  Les A Dakin; Michael H Block; Huawei Chen; Erin Code; James E Dowling; Xiaomei Feng; Andrew D Ferguson; Isabelle Green; Alexander W Hird; Tina Howard; Erika K Keeton; Michelle L Lamb; Paul D Lyne; Hannah Pollard; Jon Read; Allan J Wu; Tao Zhang; Xiaolan Zheng
Journal:  Bioorg Med Chem Lett       Date:  2012-06-06       Impact factor: 2.823

Review 2.  FDA-approved small-molecule kinase inhibitors.

Authors:  Peng Wu; Thomas E Nielsen; Mads H Clausen
Journal:  Trends Pharmacol Sci       Date:  2015-05-12       Impact factor: 14.819

Review 3.  PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers.

Authors:  Laurent Brault; Christelle Gasser; Franz Bracher; Kilian Huber; Stefan Knapp; Jürg Schwaller
Journal:  Haematologica       Date:  2010-02-09       Impact factor: 9.941

4.  Crystal structures of proto-oncogene kinase Pim1: a target of aberrant somatic hypermutations in diffuse large cell lymphoma.

Authors:  Abhinav Kumar; Valsan Mandiyan; Yoshihisa Suzuki; Chao Zhang; Julie Rice; James Tsai; Dean R Artis; Prabha Ibrahim; Ryan Bremer
Journal:  J Mol Biol       Date:  2005-04-22       Impact factor: 5.469

5.  Rational evolution of a novel type of potent and selective proviral integration site in Moloney murine leukemia virus kinase 1 (PIM1) inhibitor from a screening-hit compound.

Authors:  Hirofumi Nakano; Nae Saito; Lorien Parker; Yukio Tada; Masanao Abe; Keiko Tsuganezawa; Shigeyuki Yokoyama; Akiko Tanaka; Hirotatsu Kojima; Takayoshi Okabe; Tetsuo Nagano
Journal:  J Med Chem       Date:  2012-05-17       Impact factor: 7.446

6.  Structural basis of constitutive activity and a unique nucleotide binding mode of human Pim-1 kinase.

Authors:  Kevin C Qian; Lian Wang; Eugene R Hickey; Joey Studts; Kevin Barringer; Charline Peng; Anthony Kronkaitis; Jun Li; Andre White; Sheenah Mische; Bennett Farmer
Journal:  J Biol Chem       Date:  2004-11-03       Impact factor: 5.157

7.  Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes.

Authors:  Shannon M Mumenthaler; Patricia Y B Ng; Amanda Hodge; David Bearss; Gregory Berk; Sarath Kanekal; Sanjeev Redkar; Pietro Taverna; David B Agus; Anjali Jain
Journal:  Mol Cancer Ther       Date:  2009-10       Impact factor: 6.261

8.  Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells.

Authors:  Lisa S Chen; Sanjeev Redkar; David Bearss; William G Wierda; Varsha Gandhi
Journal:  Blood       Date:  2009-09-04       Impact factor: 22.113

9.  Flexibility of the P-loop of Pim-1 kinase: observation of a novel conformation induced by interaction with an inhibitor.

Authors:  Lorien J Parker; Hisami Watanabe; Keiko Tsuganezawa; Yuri Tomabechi; Noriko Handa; Mikako Shirouzu; Hitomi Yuki; Teruki Honma; Naoko Ogawa; Tetsuo Nagano; Shigeyuki Yokoyama; Akiko Tanaka
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2012-07-31

10.  High-throughput retroviral tagging to identify components of specific signaling pathways in cancer.

Authors:  Harald Mikkers; John Allen; Puck Knipscheer; Like Romeijn; Augustinus Hart; Edwin Vink; Anton Berns; Lieke Romeyn
Journal:  Nat Genet       Date:  2002-08-19       Impact factor: 38.330

View more
  4 in total

1.  Azaindole therapeutic agents.

Authors:  Damoder Reddy Motati; Radhika Amaradhi; Thota Ganesh
Journal:  Bioorg Med Chem       Date:  2020-10-30       Impact factor: 3.641

Review 2.  The Role of PIM Kinases in Pediatric Solid Tumors.

Authors:  Janet Rae Julson; Raoud Marayati; Elizabeth Ann Beierle; Laura Lee Stafman
Journal:  Cancers (Basel)       Date:  2022-07-22       Impact factor: 6.575

3.  Development of Potent PfCLK3 Inhibitors Based on TCMDC-135051 as a New Class of Antimalarials.

Authors:  Amit Mahindra; Omar Janha; Kopano Mapesa; Ana Sanchez-Azqueta; Mahmood M Alam; Alfred Amambua-Ngwa; Davis C Nwakanma; Andrew B Tobin; Andrew G Jamieson
Journal:  J Med Chem       Date:  2020-08-11       Impact factor: 7.446

4.  Structure-Based Virtual Screening and De Novo Design of PIM1 Inhibitors with Anticancer Activity from Natural Products.

Authors:  Hwangseo Park; Jinwon Jeon; Kewon Kim; Soyeon Choi; Sungwoo Hong
Journal:  Pharmaceuticals (Basel)       Date:  2021-03-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.